Autoimmune Hepatitis: When Your Immune System Attacks Your Liver

Overview

Autoimmune hepatitis (AIH) is a chronic inflammatory disease where the body's immune system mistakenly attacks healthy liver cells, causing inflammation and damage. Unlike viral hepatitis, which is caused by infection, autoimmune hepatitis results from a malfunction of the immune system.

The disease can range from mild with few symptoms to severe with rapid progression to cirrhosis. What makes AIH particularly challenging is its unpredictable nature - it can remain stable for years or suddenly flare without warning. However, with proper treatment, most patients can achieve remission and live normal lives.

AIH was first described in the 1950s as "chronic active hepatitis" in young women. Our understanding has evolved significantly since then, leading to better diagnostic criteria and more effective treatments. Today, we recognize AIH as a complex disorder that can affect people of all ages, genders, and ethnicities, though certain groups are at higher risk.

How Autoimmune Hepatitis Develops

In a healthy immune system, T-cells and antibodies protect the body from foreign invaders while recognizing and ignoring the body's own cells. In AIH, this recognition system fails:

1. Loss of tolerance: The immune system loses its ability to recognize liver cells as "self"
2. Activation: T-cells become activated against liver proteins
3. Inflammation: Immune cells infiltrate the liver, causing inflammation
4. Damage: Ongoing inflammation damages liver cells (hepatocytes)
5. Fibrosis: Repeated damage leads to scarring
6. Cirrhosis: Without treatment, extensive scarring develops

Types of Autoimmune Hepatitis

AIH is classified into two main types based on the autoantibodies present in the blood:

Type 1 Autoimmune Hepatitis

• Most common form (80-90% of cases)
• Can occur at any age
• Positive for antinuclear antibodies (ANA) and/or anti-smooth muscle antibodies (ASMA)
• May also have anti-SLA/LP antibodies
• Often associated with other autoimmune diseases
• Generally responds well to standard treatment

Type 2 Autoimmune Hepatitis

• Less common (10-20% of cases)
• Usually affects children and young adults
• Positive for anti-LKM1 and/or anti-LC1 antibodies
• More likely to present acutely
• Higher risk of progression to cirrhosis
• May be harder to treat

Seronegative Autoimmune Hepatitis

Some patients have all the features of AIH but test negative for typical autoantibodies. This is called seronegative AIH and represents about 10-20% of cases. Diagnosis is more challenging and often requires liver biopsy.

Overlap Syndromes

Some patients have features of AIH plus another autoimmune liver disease:

• AIH-PBC overlap: Features of both AIH and primary biliary cholangitis
• AIH-PSC overlap: Features of both AIH and primary sclerosing cholangitis
• Autoimmune sclerosing cholangitis: Mainly in children, combines features of AIH and PSC

Causes and Risk Factors

The exact cause of autoimmune hepatitis remains unknown, but it likely results from a combination of genetic susceptibility and environmental triggers in a process called "molecular mimicry."

Genetic Factors

AIH has a strong genetic component, though it's not directly inherited:

• HLA associations: Specific HLA types increase risk
  • HLA-DR3 and HLA-DR4 in Type 1 AIH
  • HLA-DR7 in Type 2 AIH
• Family history: 40% have family members with autoimmune diseases
• Genetic variations: Multiple genes affect immune regulation

Environmental Triggers

Potential triggers that may initiate AIH in genetically susceptible individuals:

• Viral infections:
  • Hepatitis A, B, or C
  • Epstein-Barr virus
  • Measles virus
  • Cytomegalovirus
• Medications:
  • Minocycline (acne medication)
  • Nitrofurantoin (antibiotic)
  • Hydralazine (blood pressure)
  • Methyldopa (blood pressure)
  • Statins (cholesterol)
  • TNF-alpha inhibitors
  • Immune checkpoint inhibitors
• Herbal supplements: Black cohosh, kava, and others

Risk Factors

• Gender: Women 4 times more likely to develop AIH
• Age: Can occur at any age but peaks in adolescence and middle age
• Other autoimmune diseases: Increases risk significantly
• Family history: First-degree relatives have higher risk
• Geography: More common in Northern Europeans

Symptoms

Autoimmune hepatitis presentation varies widely, from asymptomatic to acute liver failure. About 25-35% of patients have no symptoms at diagnosis and are identified through abnormal liver tests.

Common Initial Symptoms

• Fatigue: Most common symptom, often severe and disabling
• Abdominal discomfort: Usually right upper quadrant
• Joint pain: Small joints of hands and knees
• Muscle aches: Generalized myalgia
• Loss of appetite: May lead to weight loss
• Nausea: Intermittent, worse with fatty foods
• Low-grade fever: Persistent or recurring
• Amenorrhea: Loss of menstrual periods in women

Acute Presentation (40% of cases)

• Jaundice: Yellow skin and eyes
• Dark urine: Tea or cola-colored
• Pale stools: Clay-colored
• Severe fatigue: Profound weakness
• Anorexia: Complete loss of appetite
• Fever: May be high
• Abdominal pain: May be severe

Signs of Advanced Disease

• Spider angiomas: Small red spider-like blood vessels on skin
• Palmar erythema: Red palms
• Ascites: Fluid accumulation in abdomen
• Edema: Swelling in legs and feet
• Easy bruising: Due to clotting problems
• Confusion: Hepatic encephalopathy
• Variceal bleeding: Vomiting blood or black stools

Associated Autoimmune Conditions

Up to 50% of AIH patients have other autoimmune diseases:

• Thyroid disease (Hashimoto's or Graves')
• Type 1 diabetes
• Rheumatoid arthritis
• Sjögren's syndrome
• Systemic lupus erythematosus
• Celiac disease
• Ulcerative colitis
• Vitiligo
• Autoimmune hemolytic anemia

Diagnosis

Diagnosing autoimmune hepatitis requires a combination of clinical, laboratory, and histological findings while excluding other causes of liver disease. The International Autoimmune Hepatitis Group has developed scoring systems to aid diagnosis.

Laboratory Tests

Liver Function Tests

• Aminotransferases (ALT/AST): Usually elevated 5-10 times normal
• Alkaline phosphatase: Normal or mildly elevated
• Bilirubin: Variable, high in acute presentation
• Albumin: Low in advanced disease
• Prothrombin time: Prolonged in severe cases

Autoantibody Testing

• ANA (Antinuclear antibodies): Positive in 50-75% of Type 1
• ASMA (Anti-smooth muscle antibodies): Positive in 80% of Type 1
• Anti-LKM1: Defines Type 2 AIH
• Anti-LC1: Often with anti-LKM1 in Type 2
• Anti-SLA/LP: Highly specific for AIH
• pANCA: May be positive

Immunoglobulin Levels

• IgG: Elevated in 85% (>1.5 times normal)
• IgM: Usually normal (elevated suggests PBC)
• IgA: Usually normal

Liver Biopsy

Essential for diagnosis and assessing disease severity. Characteristic findings include:

• Interface hepatitis: Inflammation at portal-parenchymal interface
• Lymphoplasmacytic infiltrate: Dense inflammatory cells
• Hepatocyte rosettes: Regenerating liver cells in circular pattern
• Emperipolesis: Lymphocytes within hepatocytes
• Fibrosis: Variable degree of scarring

Diagnostic Criteria

Simplified diagnostic criteria for AIH include:

1. Autoantibodies (ANA or ASMA ≥1:40, or anti-LKM1 ≥1:40, or anti-SLA positive)
2. IgG above normal limit
3. Compatible liver histology
4. Absence of viral hepatitis

Differential Diagnosis

Other conditions that must be excluded:

• Viral hepatitis (A, B, C, E)
• Drug-induced liver injury
• Alcoholic liver disease
• Non-alcoholic fatty liver disease
• Primary biliary cholangitis
• Primary sclerosing cholangitis
• Wilson disease (in patients <40 years)
• Alpha-1 antitrypsin deficiency
• Celiac disease

Treatment

The goal of treatment is to achieve complete biochemical and histological remission while minimizing medication side effects. Most patients require lifelong therapy.

First-Line Treatment

Standard Induction Therapy

Two equally effective options:

Option 1: Prednisone Monotherapy

• Initial dose: 60 mg/day
• Gradual taper over weeks to months
• Maintenance: 5-10 mg/day
• Higher side effect profile

Option 2: Combination Therapy (Preferred)

• Prednisone: 30 mg/day initially
• Azathioprine: 50-100 mg/day (1-2 mg/kg)
• Lower steroid doses mean fewer side effects
• Check TPMT levels before starting azathioprine

Budesonide Alternative

• For non-cirrhotic patients
• 9 mg/day with azathioprine
• Fewer systemic steroid side effects
• Not effective in cirrhosis due to portosystemic shunting

Maintenance Therapy

After achieving remission (normal liver tests):

• Continue treatment for at least 2 years
• Azathioprine monotherapy often sufficient
• Lowest effective prednisone dose if needed
• Regular monitoring essential

Second-Line Treatments

For patients who don't respond to or can't tolerate standard therapy:

Mycophenolate Mofetil (MMF)

• Dose: 1-2 g/day in divided doses
• Well-tolerated alternative
• Teratogenic - avoid in pregnancy
• May cause GI side effects

Tacrolimus

• Calcineurin inhibitor
• Target trough levels: 3-8 ng/mL
• Effective but nephrotoxic
• Requires drug level monitoring

Other Options

• Cyclosporine: Alternative calcineurin inhibitor
• Sirolimus: mTOR inhibitor
• Infliximab: Anti-TNF for refractory cases
• Rituximab: Anti-CD20 monoclonal antibody

Treatment Response

Complete Response (Goal)

• Normal ALT and AST
• Normal IgG
• Normal liver histology

Incomplete Response

• Improvement but not normalization
• May need dose adjustment
• Consider alternative therapy

Treatment Failure

• No improvement after 4 weeks
• Worsening despite therapy
• Requires immediate reassessment

Treatment Withdrawal

Considered only after:

• Normal liver tests for ≥2 years
• Normal liver histology
• No other autoimmune diseases
• Close monitoring after withdrawal
• 80% relapse rate - most need lifelong therapy

Monitoring and Follow-up

Regular monitoring is essential to assess treatment response, detect relapses, and screen for complications.

During Induction Therapy

• Liver tests: Every 2 weeks initially, then monthly
• Complete blood count: Monitor for azathioprine toxicity
• Glucose: Check for steroid-induced diabetes
• Bone density: Baseline DEXA scan if long-term steroids expected

During Maintenance

• Liver tests: Every 3-6 months
• IgG levels: Every 6-12 months
• Complete blood count: Every 3-6 months
• Cancer screening: Skin exams (increased risk with azathioprine)

Surveillance for Complications

• Hepatocellular carcinoma: Ultrasound every 6 months if cirrhotic
• Varices: Endoscopy if cirrhotic
• Osteoporosis: DEXA scan every 2-3 years on steroids
• Metabolic complications: Lipids, glucose, blood pressure

Complications

Disease-Related Complications

Cirrhosis

• Develops in 10-15% despite treatment
• Higher risk with delayed diagnosis
• Requires enhanced surveillance
• May need liver transplantation

Hepatocellular Carcinoma

• Annual risk 1-2% in cirrhotic patients
• Can occur in non-cirrhotic AIH (rare)
• Regular surveillance crucial

Acute Liver Failure

• Rare but life-threatening
• May be initial presentation
• Requires immediate treatment
• May need emergency transplant

Treatment-Related Complications

Corticosteroid Side Effects

• Weight gain and moon face
• Osteoporosis and fractures
• Diabetes mellitus
• Hypertension
• Cataracts and glaucoma
• Mood changes and insomnia
• Increased infection risk
• Skin thinning and bruising

Azathioprine Side Effects

• Bone marrow suppression
• Increased infection risk
• Nausea and vomiting
• Pancreatitis (3%)
• Hepatotoxicity (rare)
• Increased skin cancer risk
• Lymphoma (rare)

Living with Autoimmune Hepatitis

While AIH is a serious chronic condition, most patients can lead normal, productive lives with proper treatment and lifestyle modifications.

Diet and Nutrition

• Balanced diet: No specific restrictions unless cirrhotic
• Calcium and Vitamin D: Important if on steroids
• Limit salt: If fluid retention present
• Avoid alcohol: Can worsen liver inflammation
• Maintain healthy weight: Obesity can worsen liver disease

Exercise and Activity

• Regular exercise improves fatigue
• Weight-bearing exercise for bone health
• Start slowly and increase gradually
• Avoid contact sports if low platelets

Medications to Avoid

• Acetaminophen: Limit to <2g/day
• NSAIDs: Use cautiously, especially if cirrhotic
• Herbal supplements: Many can be hepatotoxic
• Always inform providers about AIH

Vaccinations

• Hepatitis A and B vaccines recommended
• Annual flu vaccine
• Pneumococcal vaccine
• COVID-19 vaccination
• Avoid live vaccines if immunosuppressed

Emotional Well-being

• Chronic illness can cause anxiety and depression
• Support groups helpful
• Counseling may benefit
• Stress management important

Work and Insurance

• Most patients can work normally
• May need accommodations during flares
• Ensure adequate health insurance
• Consider disability insurance

Pregnancy and Autoimmune Hepatitis

With careful planning and monitoring, most women with AIH can have successful pregnancies.

Pre-Pregnancy Planning

• Achieve disease remission before conception
• Discuss medications with hepatologist
• Switch from mycophenolate (teratogenic)
• Optimize bone health
• Update vaccinations

Safe Medications During Pregnancy

• Prednisone: Safe, doesn't cross placenta easily
• Azathioprine: Generally considered safe
• Tacrolimus: Can be used if needed

Pregnancy Management

• Monthly liver tests
• High-risk obstetric care
• Monitor for gestational diabetes
• Continue immunosuppression
• Watch for postpartum flares

Outcomes

• Most have successful pregnancies
• Higher risk of prematurity
• Small increased risk of fetal loss
• Flares common postpartum (25%)
• Breastfeeding usually safe

Autoimmune Hepatitis in Children

AIH in children has some unique characteristics requiring specialized pediatric hepatology care.

Differences from Adult AIH

• More acute presentations
• Type 2 AIH more common
• Often more aggressive disease
• Better treatment response
• Growth concerns with steroids

Diagnosis Challenges

• May present as acute liver failure
• Can mimic Wilson disease
• Overlap with sclerosing cholangitis common
• Family history important

Treatment Considerations

• Same medications as adults
• Weight-based dosing
• Monitor growth and development
• Transition planning for adolescents
• Adherence challenges in teens

Long-term Outlook

• Generally good with treatment
• Most achieve remission
• Lifelong therapy usually needed
• Normal lifespan expected

Prognosis

The outlook for autoimmune hepatitis has improved dramatically with modern treatment.

With Treatment

• Remission rates: 80-90% achieve biochemical remission
• 10-year survival: >90% with treatment
• 20-year survival: 80% with treatment
• Normal lifespan: Possible with early diagnosis and treatment

Without Treatment

• 50% mortality within 5 years
• 40% develop cirrhosis within 3 years
• Progression to liver failure common

Factors Affecting Prognosis

Favorable Factors:

• Early diagnosis and treatment
• Good initial treatment response
• Type 1 AIH
• Mild histological activity
• Adherence to therapy

Unfavorable Factors:

• Cirrhosis at diagnosis
• Acute severe presentation
• Young age at onset
• Type 2 AIH
• Multiple relapses
• Poor treatment adherence

Liver Transplantation

• Excellent option for end-stage disease
• 5-year survival: 75-85%
• AIH can recur in 20-25%
• De novo AIH can develop

Latest Research

Research continues to improve our understanding and treatment of AIH.

New Therapeutic Approaches

• JAK inhibitors: Targeting inflammation pathways
• B-cell depletion: Rituximab and newer agents
• Regulatory T-cell therapy: Restoring immune tolerance
• Antifibrotic agents: Preventing cirrhosis

Biomarker Development

• MicroRNAs for diagnosis
• Predictors of treatment response
• Non-invasive fibrosis markers
• Personalized medicine approaches

Clinical Trials

Current areas of investigation:

• Steroid-free regimens
• Novel immunosuppressants
• Combination therapies
• Treatment withdrawal strategies

Resources and Support

Patient Organizations

• Autoimmune Hepatitis Association: Patient education and support
• American Liver Foundation: Comprehensive liver disease resources
• Global Liver Institute: Advocacy and research updates

Finding Specialists

• Seek hepatologist with AIH expertise
• Academic medical centers often best
• Consider second opinions for complex cases
• Pediatric hepatologist for children

Support Services

• Online support groups
• Local support meetings
• Mental health counseling
• Nutritional counseling
• Social work services

Questions for Your Doctor

• What type of AIH do I have?
• How severe is my liver damage?
• What are my treatment options?
• How often do I need monitoring?
• What side effects should I watch for?
• Can I ever stop treatment?
• Should family members be tested?
• What about pregnancy planning?